drugset / Trial / NCT05181852
Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model
RandomizedCrossoverDouble-blindTreatment
Summary
This is a Phase I, randomised, double-blind, placebo-controlled, 4-way crossover study to investigate the PD effects, safety, tolerability and PK/PD correlation of two single oral dose levels of IP2015 compared to 300 mg pregabalin and placebo in healthy male subjects using the ID capsaicin model.
Timeline
- Start
- 2022-01-05
- Primary completion
- 2022-05-30
- Completion
- 2022-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pregabalin | Small molecule | 300 mg | — |
| Subject | Pudafensine | Small molecule | — | Oral |
Indications
No indication recorded.